Multiple myeloma staging

	Multiple myeloma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple Myeloma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Multiple myeloma staging On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple myeloma staging All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple myeloma staging
CDC on Multiple myeloma staging
Multiple myeloma staging in the news
Blogs on Multiple myeloma staging
Directions to Hospitals Treating Multiple myeloma
Risk calculators and risk factors for Multiple myeloma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]; Haytham Allaham, M.D. [3]; Shyam Patel [4]

Overview[edit | edit source]

Multiple myeloma may be divided into three stages based on either the International Staging System (ISS) or Durie-Salmon Staging System.^[1] The International Staging System for multiple myeloma was published by the International Myeloma Working Group in 2003 and is the most widely used staging system.^[1]^[2] It is used for both guiding treatment as well as predicting prognosis. The Durie-Salmon staging system, first published in 1975, is a clinical staging system for multiple myeloma that correlates measured myeloma cell mass to the presenting clinical features, response to treatment, and survival.^[3] Durie-Salmon Staging System is still in use, but has been largely superseded by the more practical ISS and revised ISS ^[1]

Staging[edit | edit source]

International Staging System[edit | edit source]

According to the International Staging System (ISS), there are three stages of multiple myeloma based on both β₂-microglobulin and albumin levels:^[1] ^[2]


Stage	Features	Prognosis

Stage 1	β₂-microglobulin <3.5 mg/L and albumin ≥3.5 g/dL	Median survival of 62 months
Stage 2	β₂-microglobulin <3.5 and albumin <3.5 or β₂-microglobulin 3.5-5.5 mg/L	Median survival of 45 months
Stage 3	β₂-microglobulin >5.5	Median survival of 29 months

Revised International Staging System[edit | edit source]

The Revised International Staging System (R-ISS) was proposed in 2015 and incorporated chromosomal aberrations and LDH level to more accurately risk stratify patients.^[4]


Stage	Features	Prognosis

Stage 1	β₂-microglobulin <3.5 mg/L and albumin ≥3.5 g/dL and Absence of high-risk chromosomal abnormalities such as del(17p), t(4;14), or t(14;16) and Normal LDH level	5-year overall survival of 82% 5-year progression-free survival of 55%
Stage 2	Not Stage 1 or Stage 3	5-year overall survival of 62% 5-year progression-free survival of 36%
Stage 3	β₂-microglobulin >5.5 mg/L, and Presence of high-risk chromosomal abnormalities such as del(17p), t(4;14), t(14;16) or Elevated LDH level	5-year overall survival of 40% 5-year progression-free survival of 24%

Durie-Salmon Staging System[edit | edit source]

According to the Durie-Salmon Staging System, there are three stages of multiple myeloma based on the hemoglobin level, calcium level, skeletal survey, serum paraprotein level, and urinary light chain excretion:^[1]


Stage	Hemoglobin level	Calcium level	Skeletal survey	Serum paraprotein level	Urinary light chain excretion

Stage 1	>10g/dL	8.5-10.2 mg/dL	Normal or single plasmacytoma or osteoporosis	<5 g/dL if IgG or <3 g/dL if IgA	<4 g/24h
Stage 2	8.5-10g/dL	10.2-12 mg/dL	Fulfilling the criteria of neither 1 nor 3	5-7 g/dL if IgG or 3-5 g/dL if IgA	4-12 g/24h
Stage 3	<8.5g/dL	>12mg/dL	3 or more lytic bone lesions	>7g/dL if IgG or > 5 g/dL if IgA	>12g/24h

Stages 1, 2 and 3 of the Durie-Salmon staging system can be divided into A or B depending on serum creatinine:^[1]

A: serum creatinine < 2 mg/dL (< 177 umol/L)
B: serum creatinine > 2 mg/dL (> 177 umol/L)

SWOG Staging System[edit | edit source]

The Southwest Oncology Group (SWOG) staging system is not currently widely used. Unlike the other staging systems, there are four stages in the SWOG staging system.^[5]


SWOG Staging System

Stage	Features
Stage 1	β₂-microglobulin <2.5 mg/L
Stage 2	β₂-microglobulin >2.5 mg/L and <5.5 mg/L
Stage 3	β₂-microglobulin5.5 mg/L and albumin >3 g/dl
Stage 4	β₂-microglobulin>5.5 mg/L and albumin <3 g/dl

References[edit | edit source]

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 About multiple myeloma. University of California San Francisco (2015)http://cancer.ucsf.edu/research/multiple-myeloma/ Accessed on September, 18 2015
↑ ^2.0 ^2.1 Greipp PR, San Miguel J, Fonseca R, Avet-Loiseau H, Jacobson JL, Rasmussen E, Crowley J, Durie BMG. Development of an international prognostic index (IPI) for myeloma: report of the international myeloma working group. Hematology Journal 2003;4:S42. NLM ID 100965523.
↑ Durie BG, Salmon SE (1975). "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival". Cancer. 36 (3): 842–54. PMID 1182674.
↑ Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L; et al. (2015). "Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group". J Clin Oncol. 33 (26): 2863–9. doi:10.1200/JCO.2015.61.2267. PMC 4846284. PMID 26240224.
↑ Choi JH, Yoon JH, Yang SK (2007). "Clinical value of new staging systems for multiple myeloma". Cancer Res Treat. 39 (4): 171–4. doi:10.4143/crt.2007.39.4.171. PMC 2739370. PMID 19746184.

[California-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 About multiple myeloma. University of California San Francisco (2015)http://cancer.ucsf.edu/research/multiple-myeloma/ Accessed on September, 18 2015

[ISS-2] 2.0 ^2.1 Greipp PR, San Miguel J, Fonseca R, Avet-Loiseau H, Jacobson JL, Rasmussen E, Crowley J, Durie BMG. Development of an international prognostic index (IPI) for myeloma: report of the international myeloma working group. Hematology Journal 2003;4:S42. NLM ID 100965523.

[pmid1182674-3] Durie BG, Salmon SE (1975). "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival". Cancer. 36 (3): 842–54. PMID 1182674.

[pmid26240224-4] Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L; et al. (2015). "Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group". J Clin Oncol. 33 (26): 2863–9. doi:10.1200/JCO.2015.61.2267. PMC 4846284. PMID 26240224.

[pmid19746184-5] Choi JH, Yoon JH, Yang SK (2007). "Clinical value of new staging systems for multiple myeloma". Cancer Res Treat. 39 (4): 171–4. doi:10.4143/crt.2007.39.4.171. PMC 2739370. PMID 19746184.

[1]

[2]

[3]

[4]

[5]